Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET
WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to provide an update on DYNE-101 in myotonic dystrophy type 1 (DM1) tomorrow, June 17, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event.
Investor Conference Call and Webcast
The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne's website, and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be available. To view the live webcast and replay, please visit https://investors.dyne-tx.com/news-and-events/events-and-presentations.
About Dyne Therapeutics
Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts:InvestorsMia Tobiasir@dyne-tx.com 781-317-0353
MediaStacy Nartkersnartker@dyne-tx.com 781-317-1938
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Equinix's Rising Cash Flow Positions It as a Next Generation Dividend Aristocrat
Equinix, Inc. (NASDAQ:EQIX) is one of the . The company may be better known for its real estate investment trust (REIT) operations than for its dividends, but its dividend profile is gaining serious attention. Analysts are increasingly optimistic about the company's ability to grow its payouts, especially since REITs are often among the most attractive dividend-paying investments. A team of IT professionals working on a digital platform, indicating the company's agile digital services. Since transitioning to a REIT in 2015, Equinix, Inc. (NASDAQ:EQIX) has raised its dividend every year. With demand for data center space accelerating due to ongoing digitalization, the company projects annual revenue growth of 8% to 10% through 2027, reaching around $12 billion. This growth is expected to fuel a 7% to 10% yearly increase in adjusted funds from operations (FFO) per share. Backed by this rising cash flow and a payout ratio of over 67%, Equinix, Inc. (NASDAQ:EQIX) expects that it can grow its dividend at an annual rate of over 10% in the coming years. The company also expects to pay out $1.8 billion in dividends in 2025. In the past five years, Equinix, Inc. (NASDAQ:EQIX) has raised its payouts by nearly 12%, and it currently offers a quarterly dividend of $4.69 per share. The stock has a dividend yield of 2.10%, as of June 14. While we acknowledge the potential of EQIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
Yahoo
35 minutes ago
- Yahoo
Amgen's Strong Cash Flow Supports Reliable Dividend Payments
Amgen Inc. (NASDAQ:AMGN) is one of the . The company has built a solid track record of dividend growth, supported by consistent cash generation. In the first quarter of 2025, it generated $1.0 billion in free cash flow, up from $0.5 billion in the same period of 2024. The increase was partly due to a one-time $800 million tax payment made in Q1 2024, along with improved business performance, though partially offset by working capital timing and higher capital spending. A pharmacist filling a prescription for a complex drug developed by the company. Amgen Inc. (NASDAQ:AMGN)'s operating cash flow for the quarter rose to $1.4 billion, compared to $0.7 billion a year earlier. During this period, the company returned $1.3 billion to shareholders through dividends, highlighting its ongoing focus on delivering value. As of March 31, 2025, the company held $8.8 billion in cash and cash equivalents, with total debt standing at $57.4 billion. Alongside its consistent dividend growth, Amgen Inc. (NASDAQ:AMGN) stands out as a strong dividend contender due to its modest payout ratio of 44%. This indicates it distributes a sustainable portion of its earnings as dividends while maintaining financial flexibility. Despite significant investments in research and development, the company manages to reward shareholders without straining its balance sheet. Since initiating its dividend in 2011, the company has increased its payout every year. Over the past ten years, the dividend has grown by an impressive 201.3%. It offers a quarterly dividend of $2.38 per share and has a dividend yield of 3.22%, as of June 14. Amgen Inc. (NASDAQ:AMGN) is focused on discovering, developing, producing, and delivering cutting-edge medicines that support millions of patients in battling some of the most challenging diseases worldwide. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
an hour ago
- Business Insider
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on June 10, 2025, the company granted inducement awards to seventeen new employees. The grants were made pursuant to Nurix's 2024 Equity Inducement Plan as an inducement material to the employees' acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted stock options to purchase an aggregate of 97,400 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 66,750 shares of Nurix common stock. One fourth of the total number of shares underlying the stock options will vest on the one-year anniversary of the employee's date of hire and one forty-eighth of the total number of shares underlying the stock options will vest each month thereafter until the stock option is fully vested on the fourth anniversary of the employee's date of hire, subject to the employee's continued service with Nurix on each such vesting date. The stock options have a term of ten years and an exercise price of $12.79 per share, which is equal to the closing price of Nurix's common stock on the grant date as reported by the Nasdaq Global Market. One fourth of the total number of shares subject to the RSUs will vest on the one-year anniversary of the RSU vesting start date, which is July 30, 2025, subject to the employee's continued service with Nurix on the vesting date. Thereafter, one sixteenth of the total number of shares subject to the RSUs shall vest quarterly, until the RSU award is fully vested on the fourth anniversary of the vesting start date, subject to the employee's continued service with Nurix on each such vesting date. About Nurix Therapeutics, Inc. Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix's partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix's dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine's next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit Elizabeth Wolffe, Ph.D. Wheelhouse Life Science Advisors lwolffe@ Media Aljanae Reynolds Wheelhouse Life Science Advisors areynolds@
